Understanding and Anticipating Therapeutic Response And Immuno-meDIated Adverse Events in Anti-cancer Immune-checkpoint Inhibition: a Tissue Biopsy Based imaGing Study
RecruitingOBSERVATIONAL
Enrollment
200
Participants
Timeline
Start Date
November 25, 2023
Primary Completion Date
November 25, 2024
Study Completion Date
November 25, 2024
Conditions
Cancer
Trial Locations (1)
29200
RECRUITING
Brest University Hospital, Brest
All Listed Sponsors
lead
University Hospital, Brest
OTHER
NCT05921123 - Understanding and Anticipating Therapeutic Response And Immuno-meDIated Adverse Events in Anti-cancer Immune-checkpoint Inhibition: a Tissue Biopsy Based imaGing Study | Biotech Hunter | Biotech Hunter